Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383767
Status:
RECRUITING
Last Update Posted:
2024-04-30
First Post:
2024-04-22
Brief Title:
A Phase III Study of ESG401 for Locally Advanced or Metastatic HRHER2- Breast Cancer
Sponsor:
Shanghai Escugen Biotechnology Co Ltd
Organization:
Shanghai Escugen Biotechnology Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-07-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-22
First Submit QC Date:
April 24 2024
Study First Post Date:
2024-04-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-17
Last Update Post Date:
2024-04-30
Last Update Post Date Type:
ACTUAL